Navigation Links
SITC Expands Global Reach, Elects Key Opinion Leaders to the Board

The Society for Immunotherapy of Cancer (SITC) is proud to welcome three international experts in cancer immunotherapy to serve on its Board of Directors. The addition of these distinguished individuals will bolster SITC’s already prominent consortium of thought leaders in the cancer immunotherapy space.

Diverse Expertise and Perspectives

The collective experience of the newly elected officials supports the Society’s position as a leader in the field, dedicated to furthering the science and application of cancer immunotherapy.

Jérôme Galon, PhD
French National Institute of Health and Medical Research, Cordeliers Research Center
“As an immunologist, I am pleased to see the progress made by the Society and our field, and wish to push forward towards the cure of cancer. I wish to foster the Society’s impact and influence by establishing relationships with key strategic partners, and to establish collaborative interactions to disseminate information on cancer immunotherapy to a broad audience,” said Dr. Galon.

SITC believes that Dr. Galon’s pursuit of networking opportunities with SITC champions at top institutions will further develop the field of cancer immunotherapy and the Society’s current initiatives.

Samir N. Khleif, MD
Georgia Regents University Cancer Center
“These are very exciting times for our field. I believe that we collectively are going to be changing the face of cancer medicine for years to come. SITC will have a major role to play in further advancing the field of immunotherapy in these exciting but challenging times of today’s funding environment and medical practice. It is great to be part of such a progressive organization. I bring the perspective of a Director of a new and dynamic cancer center with a strong commitment immunotherapy as one of the cornerstones of the GRU Cancer Center and cancer medicine in general.” said Dr. Khleif.

The Society welcomes Dr. Khleif knowing he will bring a diverse perspective due to his experience with various stakeholders in the current immunotherapy landscape. This includes perspectives from his time as advisor to the FDA, service on multiple Federal advisory panels, service on scientific advisory boards for major pharmaceutical and biotechnology companies, and his longstanding service to SITC.

Pamela S. Ohashi, PhD
Princess Margaret Cancer Centre, University Health Network
“I have been working for several years to translate research findings to clinical trials, and have learned tremendously from this process. Cancer immunology continues to be an exciting field with integral aspects from basic science to medicine, and look forward to bring to the Board a perspective from the basic sciences,” said Dr. Ohashi.

The Society looks forward to Dr. Ohashi’s contributions to the Board of Directors, specifically her Canadian perspective on issues related to immune therapy.

SITC’s newly elected officials will promote the goals and vision of Society as the leading membership-driven organization specifically dedicated to the advancement of the science and application of cancer immunology and immunotherapy. Terms will commence immediately following the SITC 2015 Annual Meeting in National Harbor, Maryland, the largest and most prestigious cancer immunotherapy meeting in the world.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a non-profit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, healthcare professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Vivere Expands Services with Acquisition of Fertility Patient Experience Company
2. Clinovo Expands Business Development Team
3. Excel Life Sciences expands services to meet Indian clinical trials opportunities
4. ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research
5. Clementia Pharmaceuticals Expands Ongoing Phase 2 Study to Include Children with Fibrodysplasia Ossificans Progressiva (FOP)
6. Cedars Sinai Expands PatientTrak system
7. Ranfac expands upon proprietary bone marrow harvesting system – adds ability to percutaneously harvest a bone dowel
8. Vivere Expands Growing National Footprint with Kentucky Fertility Institute
9. FireflySci Expands Its Flow Through Cell Group With New HPLC Flow Cell Offerings
10. Paradigm Expands Access to PCDx Personalized Medicine Service by Signing Contract with Three Rivers Provider Network
11. InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms
Post Your Comments:
(Date:1/28/2020)... (PRWEB) , ... January 28, 2020 , ... ... Better Salivary Assay Kits . The new Salivary Total Human IgG ... “By measuring total immunoglobulin G in saliva, researchers can extend the accuracy and ...
(Date:1/24/2020)... ... 2020 , ... Sierra Instruments, global leader in mass flow, ... ideal for BioPharm OEMS. Sierra also announces RedyCompact™ flow meters and ... high-precision MEMS (Micro-Electro Mechanical Systems) technology utilizing an advanced, ultra-stable no-drift CMOS (Complementary ...
(Date:1/22/2020)... FARMINGTON, Conn. (PRWEB) , ... January 21, 2020 , ... ... Cell (CTC) liquid biopsy from a simple blood draw, today announced the sale of ... UConn Health. The Rare Scope will be used in clinical cancer research. , “The ...
(Date:1/8/2020)... ... 08, 2020 , ... RMA of Connecticut , a ... their family, has announced that five of their Board-Certified reproductive endocrinologists have been ... renowned publishing company Castle Connolly has compiled the list of America’s ...
Breaking Biology Technology:
(Date:1/27/2020)... ... January 27, 2020 , ... Cytonus ... a noted investor, tech entrepreneur, and former senior management consultant at McKinsey & ... Capital, the global alternative investment firm. , “Chris Thorne has exceptional business ...
(Date:1/23/2020)... ... 2020 , ... GIOSTAR/HEAMGEN has developed and secured ... The red blood cells are made utilizing a bioreactor that permits the production ... replaces the need for a human blood donor. GIOSTAR/HEAMGEN mature red ...
(Date:1/10/2020)... N.C. (PRWEB) , ... January 09, 2020 , ... ... commercialization of bioactive spinal solutions, today announced the 510(K) clearance and commercial launch ... direct lateral interbody fusion system. , The EVOL®ha-DLIF is made of PEEK-OPTIMA ...
Breaking Biology News(10 mins):